POLEmut-MMRd/MSI tumors generally retained POLE-mutated features, including ultrahigh tumor mutational burden (TMB), early-stage disease, and favorable clinicopathological characteristics, consistent with a highly immunogenic phenotype. This evidence concerns the gene POLE and neoplasm.